Technical Analysis for INSY - Insys Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 6.96 -1.83% -0.13
INSY closed down 1.83 percent on Thursday, April 19, 2018, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 8

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical INSY trend table...

Date Alert Name Type % Chg
Apr 19 Fell Below 50 DMA Bearish 0.00%
Apr 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Apr 19 Stochastic Reached Overbought Strength 0.00%
Apr 19 Upper Bollinger Band Walk Strength 0.00%
Apr 19 Inside Day Range Contraction 0.00%
Apr 19 Above Upper BB Strength 0.00%
Apr 19 Overbought Stochastic Strength 0.00%
Apr 19 Upper Bollinger Band Touch Strength 0.00%
Apr 18 Crossed Above 50 DMA Bullish -1.83%
Apr 18 Above Upper BB Strength -1.83%

Older signals for INSY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Is INSY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.02
52 Week Low 4.1
Average Volume 584,618
200-Day Moving Average 8.2054
50-Day Moving Average 7.0245
20-Day Moving Average 6.265
10-Day Moving Average 6.422
Average True Range 0.4212
ADX 21.37
+DI 27.46
-DI 18.47
Chandelier Exit (Long, 3 ATRs ) 6.0564
Chandelier Exit (Short, 3 ATRs ) 6.9736
Upper Bollinger Band 6.9466
Lower Bollinger Band 5.5834
Percent B (%b) 1.01
BandWidth 21.758978
MACD Line -0.0777
MACD Signal Line -0.2369
MACD Histogram 0.1592
Fundamentals Value
Market Cap 505.97 Million
Num Shares 72.7 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -31.64
Price-to-Sales 2.18
Price-to-Book 1.57
PEG Ratio -0.62
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.55
Resistance 3 (R3) 7.59 7.44 7.45
Resistance 2 (R2) 7.44 7.29 7.42 7.41
Resistance 1 (R1) 7.20 7.20 7.13 7.16 7.38
Pivot Point 7.05 7.05 7.01 7.03 7.05
Support 1 (S1) 6.81 6.90 6.74 6.77 6.54
Support 2 (S2) 6.66 6.81 6.64 6.51
Support 3 (S3) 6.42 6.66 6.47
Support 4 (S4) 6.38